|Bid||6.53 x 4000|
|Ask||6.61 x 3000|
|Day's Range||6.43 - 6.67|
|52 Week Range||3.71 - 18.98|
|Beta (5Y Monthly)||3.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep. 21, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
After the markets close Sept. 21, Aurora Cannabis (NASDAQ: ACB) will release results for its fiscal fourth quarter, which ended June 30. The troubled Canadian pot company's stock is already down by about 20% year to date -- a sharp contrast to the sector benchmark Horizons Marijuana Life Sciences ETF, which is up 5% -- and the upcoming report could be pivotal in determining whether the share price gets out of the red for 2021. Investors aren't expecting to see Aurora turn a profit in the final quarter of its fiscal year, but there are other ways that the company can show it is making progress.
Aurora Cannabis Inc. (ACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's why cannabis giants such as Aurora Cannabis and Cronos Group remain high-risk bets for long-term investors. The post 3 Cannabis Stocks That Will Continue to Underperform the TSX in 2021 and Beyond appeared first on The Motley Fool Canada.